Great Danes: Two Nordic biotechs name their chief ex­ec­u­tives; Ax­el Hoos bids adieu to Glax­o­SmithK­line, be­comes CEO of small on­col­o­gy play­er

Don’t let the short week de­ceive you. Peer Re­view has a lot to get to:

→ When our Nicole De­Feud­is pro­filed new Co­di­ak CMO Jen­nifer Whel­er, she al­so wrote that Ben­ny Sorensen would be tak­ing on the role of SVP of strate­gic projects af­ter head­ing up clin­i­cal de­vel­op­ment. That didn’t last long.

We’ve learned that Sorensen has re­signed to lead Dan­ish biotech Hemab Ther­a­peu­tics as CEO. Backed by No­vo Hold­ings, Hemab is a three-year-old com­pa­ny that de­vel­ops bis­pe­cif­ic an­ti­bod­ies for rare bleed­ing dis­or­ders that had been helmed by co-founder Jo­han Faber. Sorensen, an Al­ny­lam vet, will still be con­nect­ed to Co­di­ak as a mem­ber of the sci­en­tif­ic ad­vi­so­ry board and a clin­i­cal con­sul­tant.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER